| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Roark eyes a $2B deal for Nothing Bundt Cakes; Forge Global explores a buyer; Dr. Phil's media firm faces liquidation.
Argus Research analyst David Toung maintains Thermo Fisher Scientific (NYSE:TMO) with a Buy and raises the price target from...
Thermo Fisher Scientific shares rise after announcing $8.875B acquisition of Clario, enhancing AI-powered clinical trials and d...
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced a definitive agreement to acquir...
Morgan Stanley analyst Tejas Savant maintains Thermo Fisher Scientific (NYSE:TMO) with a Overweight and raises the price tar...
UBS analyst Dan Leonard maintains Thermo Fisher Scientific (NYSE:TMO) with a Neutral and raises the price target from $500 t...
TD Cowen analyst Dan Brennan maintains Thermo Fisher Scientific (NYSE:TMO) with a Buy and raises the price target from $612 ...